| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/06/2023 | 48.32% | Truist Securities | $29 → $38 | Upgrades | Hold → Buy |
| 11/02/2023 | 32.71% | HC Wainwright & Co. | $32 → $34 | Maintains | Buy |
| 10/02/2023 | 13.19% | Truist Securities | → $29 | Reiterates | Hold → Hold |
| 08/25/2023 | 36.61% | Canaccord Genuity | $34 → $35 | Maintains | Buy |
| 08/03/2023 | 21% | Piper Sandler | $27 → $31 | Maintains | Overweight |
| 08/03/2023 | 13.19% | Truist Securities | $26 → $29 | Maintains | Hold |
| 08/03/2023 | 24.9% | HC Wainwright & Co. | $30 → $32 | Maintains | Buy |
| 05/26/2023 | 1.48% | Truist Securities | $28 → $26 | Maintains | Hold |
| 05/04/2023 | 17.1% | HC Wainwright & Co. | → $30 | Reiterates | → Buy |
| 04/11/2023 | -2.42% | SVB Leerink | → $25 | Initiates Coverage On | → Market Perform |
| 04/04/2023 | 5.39% | Piper Sandler | → $27 | Initiates Coverage On | → Overweight |
| 03/08/2023 | 24.9% | Canaccord Genuity | $33 → $32 | Maintains | Buy |
| 03/01/2023 | 17.1% | HC Wainwright & Co. | → $30 | Reiterates | → Buy |
| 02/15/2023 | -14.13% | Jefferies | $35 → $22 | Downgrades | Buy → Hold |
| 12/09/2022 | 17.1% | HC Wainwright & Co. | $33 → $30 | Maintains | Buy |
| 11/08/2022 | 9.29% | Truist Securities | $30 → $28 | Maintains | Hold |
| 08/04/2022 | 28.81% | HC Wainwright & Co. | $29 → $33 | Maintains | Buy |
| 08/01/2022 | 17.1% | Truist Securities | → $30 | Downgrades | Buy → Hold |
| 02/02/2022 | 17.1% | Canaccord Genuity | → $30 | Initiates Coverage On | → Buy |
| 01/28/2022 | 17.1% | Truist Securities | → $30 | Initiates Coverage On | → Buy |
| 06/23/2021 | 13.19% | HC Wainwright & Co. | $32 → $29 | Maintains | Buy |
| 11/27/2020 | 24.9% | HC Wainwright & Co. | $22 → $32 | Maintains | Buy |
| 11/04/2020 | -14.13% | HC Wainwright & Co. | $18 → $22 | Maintains | Buy |
| 08/05/2020 | -37.55% | Jefferies | → $16 | Downgrades | Buy → Hold |
| 02/21/2020 | -41.45% | Cantor Fitzgerald | $14 → $15 | Reiterates | → Neutral |
| 09/24/2019 | -21.94% | Jefferies | → $20 | Initiates Coverage On | → Buy |
| 09/06/2019 | -29.74% | HC Wainwright & Co. | → $18 | Initiates Coverage On | → Buy |
| 02/01/2019 | -45.36% | Cantor Fitzgerald | $20 → $14 | Downgrades | Overweight → Neutral |
| 12/12/2018 | 13.19% | Cantor Fitzgerald | $17 → $29 | Upgrades | Neutral → Overweight |
What is the target price for Corcept Therapeutics (CORT)?
The latest price target for Corcept Therapeutics (NASDAQ: CORT) was reported by Truist Securities on November 6, 2023. The analyst firm set a price target for $38.00 expecting CORT to rise to within 12 months (a possible 48.32% upside). 16 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Corcept Therapeutics (CORT)?
The latest analyst rating for Corcept Therapeutics (NASDAQ: CORT) was provided by Truist Securities, and Corcept Therapeutics upgraded their buy rating.
When is the next analyst rating going to be posted or updated for Corcept Therapeutics (CORT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Corcept Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Corcept Therapeutics was filed on November 6, 2023 so you should expect the next rating to be made available sometime around November 6, 2024.
Is the Analyst Rating Corcept Therapeutics (CORT) correct?
While ratings are subjective and will change, the latest Corcept Therapeutics (CORT) rating was a upgraded with a price target of $29.00 to $38.00. The current price Corcept Therapeutics (CORT) is trading at is $25.62, which is out of the analyst's predicted range.